This is not the latest version of this item. The latest version can be found here.
Nucleic acid delivery and nanoparticle design for COVID vaccines
Name
43577_2021_169_ReferencePDF.pdf
Size
870.59 KB
Format
Adobe PDF
Checksum (MD5)
4e7512c92dc2f7e701173a2b6e8d1f7b
Author(s)
Andresen, Jason L.
Fenton, Owen S.
Date Issued
September 14, 2021
Publisher
Springer International Publishing
Citation
Andresen, Jason L. and Fenton, Owen S. 2021. "Nucleic acid delivery and nanoparticle design for COVID vaccines."
Version
Author's final manuscript
Abstract
Abstract
Nucleic acid therapeutics offer a new paradigm to rapidly respond to global health problems. The versatility of nucleic acids, especially in RNA therapies, provides the ability to tune levels of specific protein expression, achieving downregulation through short interfering RNA (siRNA) or upregulation by messenger RNA (mRNA) administration. Recent advances in the development of delivery vehicles, including nonviral nanoparticles are crucial to overcome the innate barriers to nucleic acid delivery. Toward this end, current clinical approaches have utilized mRNA and lipid nanoparticles (LNPs) to address the COVID-19 pandemic through novel vaccine strategies, producing efficacious vaccines within one year of sequencing the SARS-CoV-2 genome. Here, we review fundamental concepts required to achieve successful nucleic acid delivery, including the design of LNP systems optimized for mRNA vaccine applications.
Graphic abstract
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1557/s43577-021-00169-2
